Introduction
This is a masked randomised controlled trial to compare the effects of targeting arterial oxygen saturations at levels of 85-89% versus 91-95% in babies born at less than 28 weeks' gestation. The composite primary outcome for the trial is mortality and major disability at age 2 years (corrected for prematurity). Secondary outcomes include retinopathy of prematurity, duration of respiratory support, oxygen therapy, chronic lung disease, growth and health service utilisation. The trial will recruit 1,200 babies from approximately 40 centres in the UK and the Republic of Ireland over a period of four years.
Background
Lung immaturity is the most serious problem facing the very preterm baby at birth. Doctors started giving such babies oxygen in the 1930s, but it was difficult to double the amount of oxygen in the inspired air using the cots and bassinettes used at this time. However this became easier once Perspex "Isolette" incubators were introduced in the 1940s, and soon after this paediatricians started to notice that a number of surviving preterm babies were becoming blind, due to a previously undescribed condition (a condition now called 'retinopathy of prematurity' [ROP]) 1 . The cause of this increasingly common problem remained a mystery for twelve years -a mystery only resolved when three small trials involving just 341 babies (three of the first randomised neonatal trials ever done) provided unequivocal evidence that the unrestricted use of supplemental oxygen was a major cause of this condition 2 . Oxygen had probably caused some 10,000 babies to become blind by the time the third of these trials was published in 1956 [3] [4] [5] . A study was also published suggesting that unrestricted oxygen had also caused an increase in the incidence of spastic diplegia 6 .
Because no way had yet been devised for measuring arterial oxygen levels in order to judge just how much oxygen each individual baby needed, clinicians were advised not to let any baby breathe more than 40% oxygen. By the time methods for measuring arterial oxygen did finally become available nearly 20 years later, some suggested that this policy might, in turn, have caused the death of ten times as many babies from lack of oxygen as had been made blind in the previous ten years by exposure to too much oxygen. Methods for periodically sampling arterial blood became available in the 1970s, methods for measuring the partial pressure of oxygen transcutaneously were developed in the 1980s, and methods for continuously monitoring arterial oxygen saturation non-invasively became available in the 1990s, but no further controlled trials were ever mounted to find out how these techniques could be used to optimise the use of oxygen 7 . Systematic Cochrane reviews confirm that important uncertainties still exist about how best to protect infants from unintended harm. Unit policies still vary widely, and there is no way of knowing which of the many strategies currently in use offers the best balance between the risk of giving too much oxygen and the risk of giving too little [8] [9] [10] .
Current position
In the UK, more than three thousand babies are currently born each year more than 12 weeks early. Two thirds of these very premature babies now survive to discharge, but most grow poorly in the first year after birth and many have respiratory problems which require further hospital admission.
A quarter have at least one major disability at two years of age, and many of these have cerebral palsy. Developmental progress, even in those with no physical disability, is a standard deviation below that of babies born at term 11, 12 .
Most very premature babies require supplemental oxygen for several weeks after birth, but high arterial oxygen tensions are known to be toxic to the developing retina, causing ROP. The optimum amount of oxygen to give remains unknown, and the only controlled trials addressing this question were done more than 50 years ago at a time when few babies as immature as 28 weeks' gestation ever survived 1, 2 . We therefore do not know whether very preterm babies should only be given enough oxygen to maintain arterial saturation a little above that experienced in utero, or enough to achieve the saturations seen in the healthy term baby after birth.
Observational studies have reported widely differing rates of ROP that seem to correlate with different approaches to oxygen use (see below). Retinal surgery is currently used to arrest disease progression before retinopathy becomes too severe, but even with surgery the corrected visual acuity in 40% of treated eyes in the CRYO-ROP trial was 6/60 or worse 10 years later 13 . However, restricting oxygen exposure to minimise this problem risks increasing early mortality, increasing the number of survivors with cerebral palsy and reducing cognitive ability in the long term survivors. One large trial in Australia -the first Benefits of Oxygen Saturation Targeting (BOOST) trial -evaluated how to optimise oxygen management in preterm babies when they are more than a month old 14 . A very much larger trial is now needed to address management at an even more critical time in the first weeks after birth 10 .
Oxygen toxicity in very premature infants
Oxygen is the most common therapy given to very premature infants. However, these infants are highly sensitive to its harmful biochemical and physiological effects. While oxygen is essential for metabolism, its by-products -free radicals and reactive oxygen species -cause tissue injury. Toxic oxygen radicals are increased in hyperoxaemia (too much arterial oxygen) and in re-oxygenation after hypoxaemia (too little arterial oxygen). Premature infants are vulnerable to oxidative stress because they lack antioxidant protection in the form of plasma radical scavengers, such as vitamin E or beta-carotene, antioxidant enzymes, such as glutathione peroxidase, and their red cells lack superoxide dismutase. Hyperoxaemia can constrict or obliterate vessels in an immature eye and brain, causing ischaemic injury. Less exposure to oxygen is a simple, logical strategy that could reduce oxidative stress and tissue injury and prevent morbidity in very premature infants. In healthy infants breathing air, arterial oxygen saturation is 90-98%, which is considered physiological. However, the optimum range of arterial oxygen to minimise organ damage, without causing hypoxic injury, in very premature infants is unknown.
Oxygen and the eye
The world's first epidemic of blindness due to ROP between 1942 and 1954 was stopped at a cost that could have been avoided had a larger trial been mounted to determine whether oxygen restriction from birth increased or decreased death and disability. More recently ROP has emerged, despite better monitoring, as a "second epidemic" but is now only a common problem in babies who would not have survived in the 1950s. In 1995, 15% of babies born at less than 26 weeks' gestation in the UK required retinal surgery 15 , a proportion that is set to rise now that it has been shown that the outcome seems to be improved by intervening sooner.
Oxygen and lung disease
High inspired oxygen concentrations contribute to chronic lung disease (bronchopulmonary dysplasia) which is associated with a poor long term outcome 16 . Improved survival has increased chronic lung disease, leading to poor growth, impaired neurodevelopment and greater health costs
Oxygen and brain injury
Oxygen therapy may also contribute to brain damage in premature infants, through oxidative stress and low cerebral blood flow. Oxidative damage to premyelinating oligodendrocytes in cerebral white matter is proposed as a cause of periventricular leukomalacia 18 -a form of white matter damage correlated with diplegic cerebral palsy. In premature infants, hyperoxia reduces cerebral blood flow velocity independently of the effects of hypocapnia or hypotension 19 .
These mechanisms may explain why hyperoxaemia was a risk factor for cerebral palsy in a study of 1,105 preterm infants 20 , its occurrence in the first eight days being associated with twice the odds of cerebral palsy at 2 years, after adjusting for other variables. The adjusted odds of cerebral palsy increased eightfold for infants with the highest versus the lowest quintiles of exposure to hyperoxaemia, indicating a dose-response effect. Importantly, hyperoxaemia was defined as an arterial oxygen tension above 60 mmHg (8 kPa), rather than the long accepted upper limit of 80 mmHg (10.7 kPa) 21 .
The STOP ROP trial 22 The 'Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity' trial published in 2000 studied 649 babies to see whether varying the amount of oxygen given to 6-10 week old babies affected the later progression of existing ROP. Any effect was marginal, but those given enough oxygen to maintain a fractional saturation of 96-99% had more adverse respiratory events, including pneumonia, and chronic lung disease requiring further oxygen and diuretic therapy, than those nursed at a lower saturation (89-94%).
The first BOOST trial
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The 'Benefits of Oxygen Saturation Targeting' (BOOST) trial mentioned above was published in 2003 and recruited 358 infants born before 30 weeks' gestation who were still receiving supplemental oxygen at a postmenstrual age of 32 weeks. Half were given a masked oximeter that aimed to maintain a functional SpO 2 of 91-94%, and half a SpO 2 of 95-98%. The aim was to see whether a higher SpO 2 improved growth and development. It did not. However, it did significantly increase the time spent in oxygen, and the use of health care resources. Masked oximeters adjusted to display values 2% below or 2% above the true SpO 2 were a major innovation used in this study. Their use required staff to aim for a display value of 93-96%, but they remained 'blind' to the oxygen saturation actually achieved. This form of 'masking' proved safe, and acceptable to staff and parents.
Observational studies
Four observational studies have suggested that a lower SpO 2 shortly after birth is associated with better short term outcomes:
1. Tin, et al. 23 found that a lower SpO 2 correlated with an improved short term outcome in infants <28 weeks' gestation. Target SpO 2 in four units ranged from 80-90% to 94-98%.
Babies in the unit targeting a fractional SpO 2 of 80-90% had less ROP surgery than those in the unit targeting a functional SpO 2 of 94-98% (6.2% v. 27.2%; 80% relative risk reduction, p < 0.01). Survivors were ventilated for a shorter time (13.9 v. 31.4 days, p<0.01), fewer needed oxygen at 36 weeks' postmenstrual age (18% v. 46%; 61% relative risk reduction, p<0.01) and fewer were below the 3 rd centile for weight at discharge (17% v. 45%, 62% relative risk reduction, p<0.01). Survival (52% v. 53%) and cerebral palsy rates (15% v. 17%) at one year were similar.
A ten year follow up study of all the survivors has now established that, while there is still significantly less visual disability in the children originally nursed in less oxygen, cognitive outcomes do not differ 24 .
2. Anderson, et al. 25 in a national survey in the US, reported less Grade III/IV ROP (2.4% v. 5.5%, p<0.001) in babies weighing <1,500g at birth, and less retinal surgery (1.3% v. 3.3%, 61% relative risk reduction , p<0.037), in units where the upper SpO 2 limit in babies over 2 weeks old was <92% v. >92%. 3. Sun 26 studied 1,544 infants weighing <1,000g in units with an upper limit SpO 2 of <95% v. >95%. Units with <95% limits had less Grade III ROP (10% v. 29%), less retinal surgery (4% v. 12 %, 67% relative risk reduction, p<0.001), less chronic lung disease (27% v. 53%, 49% relative risk reduction, p<0.001) and similar mortality (17% v. 24%). 4. Chow, et al. 27 found that a functional SpO 2 of 83-90% was associated with less Grade III/IV ROP than a SpO 2 of 90-98% in historical controls weighing <1500g at birth. From 1998 to 2001, it fell from 12.5% to 2.5% (80% relative risk reduction, p=0.01) and ROP surgery fell from 7.5% (6/80) to zero (0/188) (100% relative risk reduction, p=0.0006). Fewer infants had Grade III/ IV ROP than in the Vermont Oxford Quality Improvement Network. These 4 studies suggest that a lower SpO 2 may reduce retinal surgery by 61-100%; chronic lung disease by 49-61%; and poor growth by 62%. It is not yet possible to say with any confidence whether such care increases or decreases the number of non-disabled survivors.
Systematic reviews
Four Cochrane Collaboration systematic reviews have highlighted the serious dearth of recent controlled trial information [28] [29] [30] [31] .
Global collaboration
The outcome of this study will have a major worldwide impact on one of the most important, and least well understood, elements of the care given to babies born before retinal vascularisation is complete. However, even a trial involving more than a thousand babies would have limited capacity to show that clear short term benefits were not associated with some increase in adverse long term outcomes.
Therefore similar trials are now being planned or are funded in several countries (see Table 1 ). Because of this the Chief Investigators planning these trials have all pledged their support for a prospective meta-analysis of individual participant data from each of these studies, Neonatal Oxygenation Prospective Meta-analysis (NeOProM). This will be undertaken by Dr Lisa Askie (the lead investigator of BOOST) 14 under the supervision of Professor RJ Simes in Sydney, Australia, who is the world's leading authority on this recent development in controlled-trial strategy 32, 33 .
The BOOST-II UK trial will provide information to such a prospective meta-analysis. Without such an overview clinicians around the world will never be able to show that short term benefits are not being 'bought' at the expense of a worse long term outcome. It took clinicians 20 years to realise that the short term benefits achieved by giving dexamethasone soon after birth in these babies to limit lung damage increases the risk of a worse long term outcome 34 . The same could easily be true of oxygen -the one therapeutic agent that almost every preterm baby receives.
Unique aspects of BOOST-II UK
The BOOST-II UK trial will collect all the data necessary for the global collaboration, as described above. However, in addition, the BOOST-II UK trial will address issues not being tackled by any of the other trials. These include: a detailed description of the structural and functional retinal damage that occurs in infants within the trial; and a detailed physiological assessment of chronic lung disease at 36 weeks' postmenstrual age.
OBJECTIVES
Primary objective
To determine whether varying the concentration of inspired oxygen so as to target a low (85-89%) versus a high (91-95%) functional arterial oxygen saturation (SpO 2 ), from the day of birth until the baby is breathing air (or until the baby has reached a postmenstrual age of at least 36 weeks) affects:
1. death or severe neurosensory disability on assessment 2 years after the child was due to be born 2. the length of time the baby is judged to need respiratory support 3. the severity of any retinopathy of prematurity and its two year outcome 4. the need for surgery (for conditions such as retinopathy of prematurity, patent ductus arteriosus, post-haemorrhagic ventriculomegaly and gastrointestinal problems such as necrotising enterocolitis) 5. chronic lung disease 6. poor weight gain between birth and 36 weeks' postmenstrual age, and poor weight gain and head growth between 36 weeks' postmenstrual age and 2 years corrected for prematurity.
We intend to undertake later follow-up at age 6 years. However, in order for this follow-up to be possible, the trial cohort needs to be recruited. Funding for the proposed follow-up study will be sought at a later date.
TRIAL DESIGN
Masked randomised controlled trial.
Primary and secondary outcomes
Primary outcome
Death or serious neurosensory disability at age 2 years corrected for prematurity.
NB: neurodisability is defined as any of the following:
• a combined language and cognitive score of <85 using the Bayley Scale of Infant Development (BSID-3) 35 (this is equivalent to more than 2 standard deviations below the mean of the previous edition of the Bayley scale on which basis the trial was designed); • severe visual loss (certifiable as legally blind or partially sighted); • severe cerebral palsy (unable to walk without help at 2 years); • deafness requiring (or too severe to benefit from) a hearing aid. 
Secondary outcomes
Long term:
1. re-admissions to hospital until 2 years after delivery was due (and their cause); 2. cerebral palsy (and its severity) assessed using the Gross Motor Function Classification System 39 and the Manual Ability Classification System 40 ; 3. visual disability (certifiable as legally blind or partially sighted); 4. retinal structure when last seen for ophthalmic review; 5. deafness requiring (or too severe to benefit from) a hearing aid; 6. developmental delay using the Bayley (BSID-3) cognitive score < 70 35 ; 7. other serious disability not classifiable as neurosensory in origin 41 ; 8. all postneonatal (>27 day) deaths, together with their immediate and underlying cause; 9. change in weight and head circumference from 36 weeks' postmenstrual age to 2 years after delivery was due.
Details of study design and procedures
The study is a masked randomised controlled trial. The trial design and procedures are summarised in Figure 1 and described in more detail in subsequent sections.
Figure 1
Eligibility Criteria
• < 28 weeks' gestation at birth.
• < 12 hours old (24 hours old if the baby is out-born)
• the clinician and parents are substantially uncertain which SpO 2 is better • written informed consent 
Informed consent
Informed written consent will be sought from a parent after they have been given a full verbal and written explanation of the study. The attending clinician will also meet with the parents during the intervention period to ensure that they understand the trial procedures and continue to consent to participate in the trial.
Studies show that the need to seek informed consent is best handled as a staged process rather than a single isolated event 42 .
Some preliminary written and verbal information will, whenever possible, be offered to the parents prior to birth if the baby is likely to be eligible.
Additional information will be given once the baby has been born. This can be provided at the participating centre, or in the case of neonatal transfers, this written information can be provided to the parents by the referring centre.
Further information about the trial will continue to be given to parents as and when they request it after the baby has been randomised into the study. They will also be offered an early appointment with the senior clinician responsible for the baby's care so they can discuss participation in greater detail. At this stage it would always be made clear to the parents that they remain free to withdraw their baby from the study at any time but that, if they do withdraw their baby, we would ask them for consent to continued follow-up.
A senior investigator will be available at all times to discuss concerns raised by parents or clinicians during the course of the trial.
Information about the study will continue to be offered to parents after their baby leaves the neonatal unit or dies. A regular newsletter will be produced giving parents up to date information about the study until it has finished. Experience with other studies in this area suggests that parents of babies who die may want to receive these newsletters, and all parents will be offered the opportunity to receive this information if they wish to.
Randomisation
Randomisation is via a secure website at the National Perinatal Epidemiology Unit (NPEU) in Oxford (https://rct.npeu.ox.ac.uk/boost). A 24 hour telephone back-up system will be available 365 days of the year.
Baseline assessments
For eligible babies, clinical details will be collected at trial entry. This will include details to confirm eligibility including gestational age, time since birth and confirmation of a signed parental consent form.
Follow-up -General
Hospital mortality and other short term outcomes will be assessed from the case notes. Postneonatal deaths will be classified by an assessment panel blind to treatment allocation, as will the visual outcome of all children who undergo retinal surgery 13, 38 . An objective measure of the extent to which the need for respiratory support has caused lung damage will also be obtained using Quine's development 37 of the approach pioneered by Smith and Jones 36 when the babies reach a postmenstrual age of 36 weeks.
Over the next two years, contact will be maintained with the families to collect information on health service utilisation, developmental problems and intercurrent illnesses. Every child will undergo a clinical examination two years after they were due to be born, and have their development assessed by a health professional experienced in the use of the Bayley Scale of Infant Development 35 . Training days will be arranged in order to increase the number of clinicians able to undertake a reliable Bayley Scale of Infant Development assessment, and videotaped material used to supplement and augment this training.
Additional consent will be requested to access ophthalmology notes or to perform an ophthalmic examination for any child not currently under regular ophthalmology review at the time of their Bayley assessment.
The family will also be asked at that time to agree to a further assessment when the child is six years old if additional funding can be secured to make this possible. Such an assessment would make a very much better definition of the cognitive, behavioural and ophthalmic (including visual acuity) outcomes possible.
Follow-up -Transferred babies
If a study baby is transferred to another hospital, the Trial Co-ordinating Centre will be informed so that all babies can be followed up until discharge from hospital or death. The allocated study oximeter will accompany the baby to the new hospital with a number of Masimo sensors. Each transfer hospital will be asked to provide information relating to any of the study outcomes which may have occurred during the baby's stay in that hospital.
Research Governance
Level of responsibilities of health professionals caring for babies recruited to this study Babies recruited to the BOOST-II UK Study will be allocated a study oximeter for the duration of the baby's participation in the intervention stage of the study, from soon after birth to a maximum of 36 weeks' post menstrual age (pma). During their stay in hospital, approximately 50% of these babies will be well enough to be transferred from the level 3 Neonatal Intensive Care Unit of recruitment to another unit nearer to the baby's family residence. Sometimes there may be multiple transfers between sites.
There are therefore three levels of involvement in the BOOST-II UK Study sites: 
Recruiting site
Each recruiting site will have a nominated Principal Investigator who will delegate responsibility for the recruitment of eligible babies to the trial, to members of their team once they are satisfied that the relevant member of staff is:
1. Both competent and confident in their knowledge of the study and their ability to answer questions raised 2. Both competent and confident in obtaining informed consent from the families 3. Adequately trained by experience or have received training in GCP A log of delegated responsibilities will be maintained in the Study Site File. This site will have NHS permission for research (Research & Development Approval) and a contract between the study Sponsor (Oxford University), and the Trust. All recruiting sites have been notified to the MHRA and REC either in the original application, or as part of a notice of substantial amendment.
Continuing care site
Premature babies are often transferred from the site of initial treatment to another site, either because of capacity issues or to move a baby nearer home. This transfer may happen with as little as a few hours' notice. The co-ordinating centre will be informed about the transfer of babies to continuing care sites.
If a baby is transferred from a recruiting site to a continuing care site before the baby is 36 weeks' pma, the baby's oximeter will be transferred with the baby, whether or not the baby still requires supplemental oxygen. These sites will not be involved in any decisions about entering patients into the study or seeking consent. However, these sites will potentially be treating babies with the investigational medicinal product (IMP), oxygen, and are therefore designated as research sites for the purposes of clinical trials regulations. The nature of this study means that treatment with the IMP will be handled in the same way as routine practice.
A Principal Investigator will be identified at each of these sites who is prepared to accept responsibility for overseeing the care of this baby. All potential continuing care sites are notified to the MHRA and REC as part of the notice of substantial amendment explaining the arrangements for continuing care sites.
The treatment required by a baby transferred to this level of site is standard care, that is, if supplemental oxygen is required, the saturation levels will be monitored and the target range of saturation maintained between 88% and 92%. The only difference is that this monitoring will be achieved using the Masimo oximeter which comes with the baby from the recruiting site. Training in the use of Masimo oximeters is available for all sites unfamiliar with these monitors, however, the Masimo oximeter is essentially the same as all other makes of oximeter with which the unit will have extensive experience. All continuing care sites will also have training in the study procedures.
The level of responsibility taken on by this site is, therefore, lower than at a recruiting site and the level of approval required should reflect this. NHS permission for research (R&D approval) is required as the sites are responsible for undertaking research activities. However, the extent and content of the review by R&D offices would take into account the activities being undertaken at continuing care sites. A formal risk assessment has been undertaken by the sponsor, of which the salient features are that: the intervention is standard care in all centres (re: the use of oxygen for preterm babies and the processes of targeting oxygen saturation is universal in neonatal units); training in the use of the Masimo oximeters will be provided to sites which have not previously used this make of oximeter; trial specific training, to a level appropriate to the work, will be provided to all continuing care sites; standard operating procedures will be provided to all continuing care sites which explain the process for reporting SUSARs. These actions will be facilitated by the existing management structures of regional nurses and recruiting centre research nurses who will be tasked with following up the outcomes of babies transferred to continuing care sites to ensure that: (i) on-going training is provided if required; (ii) the study protocol is complied with; (iii) SUSARs are reported in a timely manner. The resource use and risk above standard care is therefore minimal.
Due to the short notice in transfer of babies to continuing care sites, and the inability of continuing care sites to choose whether or not to accept babies who have previously been entered into the study, it is not possible to obtain R&D approval or a signed contract between the sponsor and the continuing care site, prior to the site undertaking research responsibilities. A standard letter will be provided to continuing care sites, outlining the responsibilities of each party, in place of a standard contract between the sponsor and site, due to the timescales involved. If the R&D office, after consideration of the above information, does not give permission for the research then the baby would have to be withdrawn from the study, or transferred to another continuing care site. Where there are potential issues to address, NHS organisation could consider issuing permission, pending completion of any such arrangements.
Data collection site
Occasionally a baby will be transferred several times before it goes home. If a baby is transferred to a hospital after it is 36 weeks' pma we will request that a short discharge form is completed either when the baby is transferred from that hospital, is discharged home or dies. Parental consent to the transfer of this data to the coordinating centre will have been given as part of the initial consent process.
After 36 weeks' pma the intervention phase of the study is complete, the study oximeter will no longer be used and babies will no longer receive the IMP as part of the trial. Data collection centres will, therefore, have no responsibilities for research activities, provision of IMP, or reporting of SUSARs and do not constitute a research site under the clinical trials regulations. The provision of data collected as part of standard care to the study coordinating centre does not require any agreement of responsibilities between the sponsor and the centre, or any training.
As a baby participating in BOOST-II UK could in theory be transferred to any neonatal unit in the UK we will contact all Trust R&D departments throughout the UK to alert them to this possibility. When we are notified that a baby has been admitted to a Trust without existing approval we will contact the R&D office to inform them that routine discharge data has been requested, so that R&D offices can keep a record of involvement in the study.
Study intervention
The intervention under investigation is a strategy that aims to keep functional oxygen saturation either above or below 90% for as much of the time as possible until the child no longer needs supplemental oxygen or reaches a postmenstrual age of 36 weeks.
The oximeters
Masimo Radical pulse oximeters (Irvine, CA) will be used exclusively to monitor oxygen saturation levels because they can store data, and because they use state-of-the-art signal extraction technology which minimises artefact due to motion or low perfusion 45 .
The trial monitors will, however, be modified by the manufacturer so that, although they work as normal when saturation is below 85% or above 95%, they display and store a figure that has been 'off-set' either 3% above or 3% below the true value when arterial saturation is between 88% and 92%, and has employed tapering for intermediate values so the figure displayed does not jump suddenly as saturation changes (see Figure 2) . It is this that makes the study a 'masked' trial because the nature of the 'off-set' will only be known to the trial computing staff at the NPEU. Staff in collaborating units will be required to aim, as far as possible, for a displayed reading of 88-92%. Although units will not be required to adopt a single uniform policy with respect to trial oximeter alarm settings, they will be required to develop and maintain a consistent policy locally, to inform the Trial Co-ordinating Centre what this policy is, and to document and communicate any change in policy. In addition, all units will, as a minimum, arrange to ensure that the monitor's alarm is triggered each time the displayed functional saturation exceeds 94%, unless the baby is no longer currently receiving supplemental oxygen. Criteria for titrating inspired oxygen concentration, and for stopping oxygen therapy, will be determined by the attending clinicians and are not specified by the trial protocol.
Babies referred to other units, in order to convalesce after the initial period of intensive care, will retain a trial pulse oximeter until they reach a postmenstrual age of 36 weeks.
Duration of treatment period
Once a baby is randomised in the trial, all saturation monitoring must be achieved using a trial oximeter until the infant reaches a postmenstrual age of 36 weeks, and no other oximeter may be attached to the baby.
Minimisation of bias
The study is randomised and masked. Masking of the intervention will be achieved by modifying the oximeters to display and store a figure that is either 3% above or 3% below the 'true' oxygen saturation, as described in Section 3.3. A briefing package will be implemented in each participating centre prior to recruitment to ensure maximum compliance.
Efforts will be made to ensure high rates of follow-up for the study outcomes and high rates of completion of the data collection forms. Experience with other perinatal trials suggests that it will be possible to determine early neonatal events in all babies recruited. Loss to follow-up of the child is more problematic, although there are likely to be few children who cannot be traced either through the hospital of recruitment or the NHS Central Register (or equivalent systems in Scotland and the Republic of Ireland).
Duration of study
The trial has two phases: intervention and non-intervention. In the intervention phase (Phase 1), the trial will be described to the parents of eligible babies. Consent will be sought using several stages, as described in Section 3.2. Once a baby is randomised in the trial, all saturation monitoring must be achieved using the trial oximeter until the infant reaches a postmenstrual age of 36 weeks. The end of the intervention phase of the trial is defined as when the last baby is discharged from hospital.
In the non-intervention phase (Phase 2), children will be assessed for disability 2 years after the delivery due date. The end of the non-intervention phase of the trial is defined as when the last baby has undergone their 2 year assessment.
MHRA will be notified of the end of phase 1.
Discontinuation criteria
In accordance with the current revision of the Declaration of Helsinki (amended October 2000, with additional footnotes added 2002 and 2004, and updated 2008) and any other applicable regulations, a parent has the right to withdraw their baby from the study at any time and for any reason, without prejudice to the child's future medical care by the clinician or at the institution, and is not obliged to give his or her reasons for doing so.
The attending clinician may withdraw the baby at any time in the interests of the baby's health and well-being.
Accountability of the study treatment
The study intervention in this trial is oxygen. This will be the currently available oxygen supply at each of the participating neonatal units.
Randomisation
A computer-generated program that uses a minimisation algorithm will be used to ensure balanced allocation to the two arms of the trial from a knowledge of gestation, sex at birth and recruiting unit. The trial computing staff at the NPEU will write the randomisation program and hold the code. If necessary, the code may be broken for a single participant by the Chief Investigator.
Source data
Source data will comprise:
• hospital records for the baby's condition at birth and the short term outcomes • the specific form which records the assessment of disability at 2 years of age (corrected)
• data collection forms for the parents' report of health service utilisation • data downloaded from the Masimo oximeters
SELECTION AND WITHDRAWAL OF TRIAL PARTICIPANTS
Approximately 1,200 babies will be recruited to this trial.
Inclusion criteria
Infants are eligible if:
they are less than 28 weeks' gestation at birth and a) they are less than 12 hours old (24 hours old if the baby is out-born) and b) the clinician and parents are substantially uncertain which SpO 2 is better and c) the parent(s) have given written informed consent to their baby's participation
Exclusion criteria
Recruitment is not appropriate if there is no realistic prospect of survival, or follow-up is unlikely to be possible.
Withdrawal of participants
Babies may be withdrawn for any of the reasons given in Section 3.6, Discontinuation Criteria. The reason for withdrawal will be recorded on the data collection form. If the baby is withdrawn due to an adverse event, the Investigator will arrange for follow-up visits or telephone calls until the adverse event has resolved or stabilised.
TREATMENT OF TRIAL PARTICIPANTS
Description of intervention
Oxygen is given to all very preterm babies. The oxygen supply used will be the standard oxygen source used in each participating neonatal unit. Oxygen will be given via an endotracheal tube, or nasal cannula, or into an incubator or headbox as judged necessary by the attending clinician. This is usual practice for these babies, and their participation in the trial will not alter the route of oxygen administration.
The dose of oxygen to be given will be individually titrated against the functional oxygen saturation. The target functional oxygen saturation is either 85-89% or 91-95% until such time as supplementation is no longer required.
The intervention (i.e. saturation monitoring) will continue from the start of the study until the baby reaches a postmenstrual age of 36 weeks. After this time the baby will receive whatever oxygen supply is necessary to maintain the baby within the usual functional oxygen saturation range for that participating unit. By 36 weeks as judged necessary by the attending clinician, many babies will require no additional oxygen. Saturation monitoring after 36 weeks, if required, will use a standard oximeter (non-offset).
Concomitant medication
Throughout the study, the babies may be prescribed concomitant medications deemed necessary to provide adequate supportive care.
Compliance with Dosing Regimen
The Principal Investigator will ensure that clinical staff administering the intervention will understand how to titrate the inspired oxygen to maintain oximeter readings within the desired range, so as to maintain compliance, as described in Section 3.3.
The Masimo oximeters used in the trial contain a memory facility capable of storing SpO 2 readings for up to one month. A built-in display facility allows clinical staff to assess compliance with saturation targets on a day-to-day basis and, as an added check, all stored data will be downloaded when the monitor is returned to the NPEU. These data will be reviewed to evaluate maintenance of oxygen saturation within the target range.
A replacement oximeter is allocated every 28 days up until the time baby reaches 36 weeks. The previous oximeter is sent back to the co-ordinating centre to be downloaded. The same procedure is used for both recruiting sites and continuing care sites.
ASSESSMENT OF EFFICACY
Hospital mortality and other short term outcomes will be assessed from the case notes. Postneonatal deaths will be classified by an assessment panel blind to treatment allocation, as will the visual outcome of all children who undergo retinal surgery. A simple, non-invasive, objective measure of the extent to which the need for respiratory support has caused lung damage has been developed 37 and such an assessment will be undertaken on all babies when they reach a postmenstrual age of 36 weeks. This provides a quantitative measure of amount of residual ventilation/perfusion mismatch, while also assessing whether the child meets the NICHD 16 and/or Walsh 43 criteria for being classified as having chronic lung damage (so called 'bronchopulmonary dysplasia').
Over the next two years, contact will be maintained with the families to collect information on health service utilisation, developmental problems and intercurrent illnesses. Each child will undergo clinical examination two years after they were due to be born, and development assessed by a health professional experienced in the use of the latest version of the Bayley Scale of Infant Development (BSID-3) 35 . Training days will be arranged in order to increase the number of clinicians able to undertake a reliable BSID assessment, and videotaped material used to supplement and augment this training. Ophthalmic review will also be offered where this seems clinically appropriate.
ASSESSMENT OF SAFETY
Safety will be assessed continuously during each baby's stay in the neonatal unit. Any adverse events which require expedited reporting will follow the system outlined below (Section 7.2).
Other outcomes, which may also be considered safety outcomes, such as death or early neonatal morbidity, but which are anticipated outcomes for this group of very preterm babies, will be recorded on the data collection forms and will be reviewed by the Data Monitoring Committee at regular intervals throughout the trial.
Definitions
Adverse Event (AE)
An AE or adverse experience is:
Any untoward medical occurrence in a participant administered a medicinal product, which does not necessarily have to have a causal relationship with this treatment (the study medication).
An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), or disease temporally associated with the use of the study medication, whether or not considered related to the study medication.
Adverse Drug Reaction (ADR)
All untoward and unintended responses to a medicinal product related to any dose.
The phrase "responses to a medicinal product" means that a causal relationship between a study medication and an AE is at least a reasonable possibility, i.e. the relationship cannot be ruled out.
Unexpected Adverse Reaction
An adverse reaction, the nature or severity of which is not consistent with the treatment.
Serious or Severe Adverse Events
To ensure no confusion or misunderstanding of the difference between the terms "serious" and "severe", which are not synonymous, the following note of clarification is provided:
The term "severe" is often used to describe the intensity (severity) of a specific event (as in mild, moderate, or severe myocardial infarction); the event itself, however, may be of relatively minor medical significance (such as severe headache). This is not the same as "serious," which is based on participant/event outcome or action criteria usually associated with events that pose a threat to a participant's life or functioning. Seriousness (not severity) serves as a guide for defining regulatory reporting obligations.
Serious Adverse Event or Adverse Drug Reaction
A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:
Results in death or
Is life-threatening
The term "life-threatening" in the definition of "serious" refers to an event in which the participant was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it were more severe.
Requires in participant hospitalisation or prolongation of existing hospitalisation,
Results in persistent or significant disability/incapacity, or
Is a congenital anomaly/birth defect.
Medical and scientific judgment should be exercised in deciding whether an adverse event is serious in other situations.
Expected Adverse Drug Reactions
The only known adverse reaction associated with excess oxygen is:
Retinopathy of prematurity
Expected Serious Adverse Events (SAEs)*
The following are serious adverse events that could be reasonably expected for this group of babies during the course of the study:
• Death
• Necrotising enterocolitis or focal intestinal perforation
• Chronic lung disease
• Intracranial abnormality (haemorrhage or focal white matter damage) on cranial ultrasound scan or other imaging
• Pulmonary haemorrhage
• Patent ductus arteriosus
• Retinal surgery
• Disability at age 2 years (corrected for prematurity) including motor disability (including cerebral palsy), cognitive disability, blindness and deafness * These SAEs do not require immediate reporting
Suspected Unexpected Serious Adverse Reaction (SUSAR)
All suspected adverse reactions related to an investigational medicinal product that are both unexpected and serious.
Causality Assessment
All cases judged by either the reporting medically qualified person or the Chief Investigator as having a reasonable suspected causal relationship to the treatment qualify as ADRs.
Serious (unexpected) adverse event (SAE) reporting procedures
All unexpected SAEs must be reported to the Chief Investigator within one working day of discovery or notification of the event. A Standard Operating Procedure (SOP) outlining the reporting procedure for clinicians will be provided on the reverse of the SAE form. An SOP will also be available as part of the Trial Specific SOPs which will outline the reporting procedure for the Trial Co-ordinating Centre. All SAE information must be recorded on an SAE form and faxed to the Chief Investigator. Additional information received for a case (follow-up or corrections to the original case) need to be detailed on a new SAE form and faxed to the Chief Investigator.
Reported SAEs will be assessed for causality, expectedness and severity.
All related SAEs that result in a participant's withdrawal from the study or are present at the end of the study, should be followed up until a satisfactory resolution occurs.
The Chief Investigator will report all suspected adverse reactions which are both serious and unexpected (SUSAR/SAEs) to the Competent Authorities (MHRA/IMB) and the Ethics Committee concerned. Fatal or life-threatening SUSARs must be reported within 7 days and all other SUSARs within 15 days. In addition a copy of the SUSAR/SAE will be forwarded to the Chair of the Data Monitoring Committee. The Chair will also be provided with a document detailing all previous SUSAR/SAEs with their unblinded allocation. The Chief Investigator will also inform all investigators concerned of relevant information about SUSAR/SAEs that could adversely affect the safety of participants.
In addition to the expedited reporting above, the Chief Investigator shall submit, once a year throughout the clinical trial, or on request, a safety report to the Competent Authorities and Ethics Committee.
The severity of events will be assessed on the following scale: 1 = mild, 2 = moderate, 3 = severe.
The relationship of AEs to the study medication will be assessed according to the definition provided in Section 7.1.
STATISTICS
Description of statistical methods
Primary analysis population
The primary analysis population is defined as the population of babies targeted with an oximeter using the new algorithm (Note: the first 228 babies randomised were targeted using the old algorithm). The rationale behind this restricted primary analysis population is two-fold; (i) the change of algorithm has led to improved separation between the two randomised groups, and (ii) the new algorithm reflects saturation curves using other oximeters and hence current clinical practice.
This change of analysis population is a deviation from the original intention. Following the change of algorithm, the independent BOOST-II UK Data Monitoring Committee asked the Trial Steering Committee (TSC) in December 2009, to specify which analysis population was the most appropriate for the primary analysis; all babies, or restricted to those targeted with an oximeter using the new algorithm. The TSC agreed that the primary analysis population should be restricted to those targeted with an oximeter using the new algorithm and a secondary analysis should also be performed to include all babies stratified by algorithm. This decision by the TSC was based on knowledge that the new algorithm performed better in terms of separation between the two groups, and was now more comparable with other available oximeters 49 . Most importantly, the TSC did not have access to any data about clinical outcomes associated with the use of the old or new algorithm.
Primary analysis statistical methods
For the primary analysis, babies will be analysed in the groups to which they were randomly allocated regardless of deviation from the protocol or whether they received the allocated intervention.
Demographic factors and clinical characteristics will be summarised with counts (percentages) for categorical variables, mean (standard deviation [SD]) for normally distributed continuous variables, or median (interquartile [IQR] or entire range) for other continuous variables.
Comparative statistical analysis will entail calculating the risk ratio (RR) plus 95% confidence interval (CI) for the primary outcome (99% CIs for all other dichotomous outcomes), the mean difference (plus 99% CI) for normally distributed continuous outcomes or the median difference (plus 99% CI) for other continuous variables.
Analysis of secondary outcomes will be clearly delineated from the primary analysis in any statistical reports produced.
Pre-specified subgroup analysis
The consistency of the effect of targeting higher or lower saturation will be explored to see whether it is of particular help, or not, to specific subgroups of babies, using the statistical test of interaction. The following pre-specified subgroups will be examined for the primary outcome:
• age at recruitment (0 to <6 hours/6 or more to <12 hours/12 or more to <18 hours/18 to 24 hours) • singleton or multiple birth • sex • the factors leading to preterm birth (premature rupture of membranes (PROM); premature labour (without PROM); pregnancy induced hypertension (± APH); antepartum haemorrhage (APH); other maternal illness; poor fetal growth (mother well)
Secondary analysis
The robustness of the results will be examined by including all babies randomised in the analysis population, whether or not the baby was targeted with an oximeter using the original or updated algorithm.
Exploratory analysis
Hypothesis generating exploratory analyses will be conducted into the relationship between saturation patterns and outcome. 95% CIs will be used for these analyses acknowledging that they are exploratory and will require confirmation. As BOOST-II UK and the BOOST 2 trial in Australia/ New Zealand are recording similar compliance data, it will be possible for hypotheses to be generated in one trial and then tested in another.
Interim analyses
An independent Data Monitoring Committee (DMC) will be established, whose remit will be to review the trial's progress. The DMC will be independent of the trial organisers. Interim analyses will be supplied, in strict confidence, to the DMC, as frequently as its Chair requests. The terms of reference for the DMC will be agreed at their first meeting. A DMC charter will be completed following the recommendations of the DAMOCLES Study 46 . Meetings of the committee will be arranged periodically, as considered appropriate by the Chair. In the light of interim data on the trial's outcomes, adverse event data, accumulating evidence from other trials (see below) and any other relevant evidence (including updated overviews of the relevant randomised controlled trials), the DMC will inform the Trial Steering Committee (TSC) if in their view there is proof beyond reasonable doubt that the data indicate that any part of the protocol under investigation is either clearly indicated or contra-indicated, either for all infants or for a particular subgroup of trial participants. Unless modification or cessation of the trial is recommended by the DMC, the TSC, investigators, collaborators and administrative staff (except those who supply the confidential information) will remain ignorant of the results of the interim analysis. Collaborators and all others associated with the study may write to the DMC via the BOOST-II UK Trial Co-ordinating Centre, to draw attention to any concern they may have about the possibility of harm arising from the treatment under study. The TSC's terms of reference will be discussed and agreed at the joint DMC/TSC meeting prior to the start of recruitment.
It is intended that the Chairs of the DMCs for the trials from Australia, New Zealand, USA, Canada and the UK & Republic of Ireland will liaise over the collection of regularly updated data for a number of key short and long term outcomes which will be included in a prospective meta-analysis of individual participant data.
Each DMC will need to decide, in consultation with the other DMCs, what information it would want to see from the ongoing meta-analysis in addition to the standard data it would see from its own trial. Making recommendations about continuation or premature halting of the trial based on these data will be complex and will need to be discussed and agreed between the various DMCs before the trial commences recruitment.
Membership of the BOOST-II UK trial DMC includes:
Sir Iain Chalmers (Chair) Professor Doug Altman (independent statistician) Professor Richard W Cooke (paediatrician; vice chair) Dr Hazel McHaffie (nurse/ethicist) Ms Nancy Owens (parent)
The number of participants
Babies targeted to maintain a high oxygen saturation are expected to have a 30 to 40% rate of the composite primary outcome of mortality and major disability at two years [11] [12] . To detect an absolute risk difference (increase or decrease) of 8% or more in the primary outcome will require between 990 and 1,664 babies (see Table 2 ). Assuming that the primary event rate will be approximately 35%, then to detect an 8% absolute difference to 43% with 80% power and 5% significance requires a total sample size of approximately 1,200 babies. This sample size also gives more than 90% power to show an absolute risk reduction of 5% or more in ROP judged severe enough to merit retinal surgery, from 10% to 5%. While this is a large difference, it matches hypotheses from studies that link less oxygen with relative risk reductions of 50-100% in ROP surgery [23] [24] [25] [26] [27] . The assumed baseline prevalence of 10% 15, 23 is, in any case, probably conservative given the recent recommendation that surgery should be undertaken at an earlier stage in the disease process 47 .
In relation to the proposed prospective meta-analysis, it is anticipated that at least a further 4,000 babies will be recruited. This number will provide in excess of 80% power to exclude an absolute difference of 4% in the primary outcome which will provide greater certainty that any short term effects of the intervention are not at the cost of longer term differences in outcome.
The level of statistical significance
For the primary outcome a 95% confidence interval will be calculated, but, to take account of their number of comparisons, 99% confidence intervals will be used for the secondary outcomes.
Criteria for the termination of the trial
In the light of interim data and other evidence from relevant studies (including the global collaborative meta-analysis), the DMC will inform the TSC if, in their view, there is proof beyond reasonable doubt that the data indicate that the trial should be terminated. A decision to inform the TSC of such a finding will in part be based on statistical considerations.
Appropriate proof beyond reasonable doubt cannot be specified precisely. A difference of at least 3 standard errors in the interim analysis of a major endpoint may be needed to justify halting or modifying the study prematurely 48 .
8.5
Procedure for accounting for missing, unused, and spurious data Missing data will be described, for example, by presenting the number and percentage of individuals in the missing category.
All data collected on data collection forms will be used, since only essential data items will be collected.
No data will be considered spurious in the analysis since all data will be checked and cleaned before analysis.
Procedure for reporting deviation(s) from the original statistical plan
Deviations from the original statistical plan are unlikely. However, should they occur, then approval for such changes will be sought from the MREC and MHRA and these changes will be reported in the final report and papers.
DIRECT ACCESS TO SOURCE DATA/ DOCUMENTS
The investigator(s)/institution(s) will permit trial-related monitoring, audits, review by DMC/ Independent Ethics Committee, and regulatory inspection(s), providing direct access to source data/ documents to authorised study or regulatory personnel.
• Auditing of a random sample of source data will be undertaken during visits to centres by one of the Study Research Nurses or the Study Co-ordinator.
• A random selection of key data items will be checked.
• A small random sample of participants will be selected.
• Output from the data held in the Trial Co-ordinating Centre will be provided for the visiting member of staff.
• Any data queries or verification will be dealt with at the same time.
• Permission to inspect the baby's notes must be obtained from the Principal Investigator in the hospital to be visited.
• Baby's notes should be requested from the medical records by the visiting staff member.
QUALITY CONTROL AND QUALITY ASSURANCE PROCEDURES
Compliance with protocol will be ensured by a number of procedures:
Site set-up and training
Start-up visits will be performed before the first baby is enrolled to ensure that all staff are fully trained in BOOST-II UK procedures.
Regular site visits will be made to ensure adherence to the protocol and to deal with any specific site issues.
Nurse study days will be scheduled twice yearly to ensure all BOOST-II UK nurses are fully appraised of issues such as consent, data collection, follow-up and changing regulations.
Meetings for Principal Investigators and nurses will be organised with workshops to discuss protocol issues, data collection issues and specific BOOST-II UK procedures.
Data collection, processing and monitoring
All study data are:
• Collected using BOOST-II UK data collection forms or downloaded directly from the Masimo monitors • Processed and monitored centrally for consistency, viability and quality at the Trial Co-ordinating Centre, NPEU, University of Oxford • Screened for out-of-range data, with cross-checks for conflicting data within and between data collection forms using computerised logic checking screens • Referred back to the relevant centre for clarification in the event of missing items or uncertainty • Processed using a double data-entry system by independent data clerks.
Central statistical monitoring
All data are monitored using central statistical monitoring (at the NPEU) for consistency, viability and quality using bespoke data management systems. Central statistical monitoring is used to monitor patterns of recruitment at sites, disease severity among site populations, use of study oximeters, time of recruitment, etc. Central statistical monitoring can be utilised 'for cause' purposes if necessary.
The trial programmer runs trial-specific programs to extract certain fields from the database (as requested by the Chief Investigator (CI), or Trial Statistician (TS)) and to cross-check certain information. These fields may include measures of eligibility criteria, treatments given after trial entry and compliance.
The trial programmer and Chief Investigator will review the results generated for logic and for any patterns or problems. Outlier data will be investigated.
The Chief Investigator and Trial Statistician will decide if any action needs to be taken.
On-site monitoring
• A random sample of cases are monitored at source when site visits are performed (Source Document Verification).
• The documents to be verified are randomly selected using computerised study number generation. Any major discrepancies found at a site visit would trigger a more extensive audit of study data at the site involved.
National registration systems
All babies recruited into BOOST-II UK are 'flagged' with the appropriate agency for their country. This will help us to keep in touch with families for subsequent follow-up. We will follow-up the babies in the study by sending the names, addresses and dates of birth to the appropriate agency, they will be able to notify us of the area of residence, inform us if the family emigrate and the date and cause of death if appropriate. The following are the agencies for each country: 
Data Monitoring Committee (DMC)
The DMC will meet regularly throughout the study period to receive and review the progress and accruing data of this trial and provide advice on the conduct of the trial to the Trial Steering Committee.
The DMC will inform the Chair of the steering committee if, in their view the results are likely to convince a broad range of clinicians, including those supporting the trial and the general clinical community, that one trial arm is clearly indicated or contra-indicated, and there was a reasonable expectation that this new evidence would materially influence patient management.
The DMC will undertake interim review of the trial's progress including updated figures on recruitment, data quality, and main outcomes and safety data. The role of the DMC is to:
• assess data quality, including completeness (and by so doing encourage collection of high quality data) • monitor recruitment figures and losses to follow-up • monitor compliance with the protocol by participants and investigators • monitor evidence for treatment differences in the main efficacy outcome measures • monitor evidence for treatment harm (e.g. toxicity data, SAEs, deaths)
• decide whether to recommend that the trial continues to recruit participants or whether recruitment should be terminated either for everyone or for some treatment groups and/or some participant subgroups • suggest additional data analyses • advise on protocol modifications suggested by investigators or sponsors (e.g. to inclusion criteria, trial endpoints, or sample size) • monitor planned sample size assumptions • monitor continuing appropriateness of patient information • monitor compliance with previous DMC recommendations • consider the ethical implications of any recommendations made by the DMC • assess the impact and relevance of external evidence
ETHICS
Declaration of Helsinki
The Investigator will ensure that this study is conducted in full conformity with the current revision of 
MRC Guidelines for Good Clinical Practice (GCP)
The Investigator will ensure that this study is conducted in full conformity with relevant regulations and with the MRC GCP guidelines which are based on ICH Guidelines for GCP (CPMP/ICH/135/95) July 1996.
Informed consent
The study will be discussed and written information will be presented to the baby's parent detailing no less than: the exact nature of the study; the implications and constraints of the protocol. It will be clearly stated that the parents are free to withdraw their baby from the study at any time for any reason without prejudice to future care, and with no obligation to give the reason for withdrawal.
Babies are only eligible for the trial if they are less than 12 hours old (24 hours if out-born). Therefore, in the first instance, the parent has up to 12 hours to consider the information, and the opportunity to question the Principal Investigator and other clinical staff to decide whether they will participate in the study. However, once the baby is randomised, information about the trial will continue to be given as and when parents request, and they will be offered an appointment with the senior clinician responsible for the baby's care to discuss participation in detail.
Written informed consent will be obtained by means of parent dated signature and the signature of the person who obtained informed consent; this would be the Principal Investigator (or clinician with delegated authority). A copy of the signed informed consent will be given to the parents. A further copy will be retained in the baby's medical notes, a copy will be retained by the Principal Investigator and a final copy will be sent to the Trial Co-ordinating Centre.
Independent Ethics Committee
A copy of the protocol, proposed informed consent form, and written participant information and any proposed advertising material will be submitted to an Independent Ethics Committee for written approval.
The Chief Investigator will submit and, where necessary, obtain approval from the Independent Ethics Committee for all subsequent protocol amendments and changes to the informed consent document.
The Principal Investigator will notify deviations from the protocol or SAEs occurring at the site to the sponsor and will notify the Independent Ethics Committee of these in accordance with local procedures.
Participant confidentiality
The Chief Investigator will ensure that the baby's information is kept confidential. The baby will be identified by name (consent will have been given by the parent(s)) and study number on the data collection form. All documents will be stored securely and kept in strict confidence in compliance with the Data Protection Act (1998).
DATA HANDLING AND RECORD KEEPING
All study data will be entered into a Microsoft Access database with a Visual Basic interface to restrict access to the raw data.
Data collected on the data collection forms will be stored in an electronic database in which the baby will be identified by a study specific number. The baby's name and any other identifying details will be stored in a separate database linked only by the study number. This information will be collected with the consent of the parent(s) to enable follow-up to be undertaken. Data entered will undergo statistical analysis to produce the results of the trial. Coding is required to ensure the consistent and appropriate description of items reported on data collection forms such as concomitant medications, reasons for study entry and other medical terms that may include complications of birth.
Standard operating procedures are in place for the collection and handling of data received at the Trial Co-ordinating Centre.
Storage is on a restricted area of a file server (running Novell Netware). The server is in a secure location and access is restricted to a few named individuals. Access to the building in which NPEU is situated is via an electronic tag and individual rooms are kept locked when unoccupied. Authorisation to access restricted areas of the NPEU network is as described in the NPEU security policy.
Data will be processed on a workstation by authorised staff. The workstations access the network via a login name and password (changed regularly). No data are stored on individual workstations. Backing up is done automatically overnight to an off site storage area. The location of the backup computer is in a separate department which has electronic tag access. Access to the room in which the backup machine is located is via a key pad system.
FINANCING AND INSURANCE
The trial is funded by the Medical Research Council. The Masimo Corporation, Irvine, California, have leased pulse oximeters to the NPEU in Oxford for the duration of the first phase of this trial, but the Corporation will have no role in the conduct of the trial, the analysis of the findings, or the publication of the results.
The University of Oxford's Clinical Trials, Professional Negligence and Public Liability Insurances are all arranged through Oxford Mutual Limited. It is the University's present intention to keep this arrangement, or alternative arrangements with similar Terms and Conditions in place for the foreseeable future. The University reserves the right to place other alternative risk transfer mechanisms in place, and which will provide a level of cover in line with those presently arranged through the insurance market.
PUBLICATION POLICY
The Chief Investigator will co-ordinate dissemination of data from this study. All publications using data from this study to undertake original analyses will be submitted to the TSC for review before release.
To safeguard the scientific integrity of the trial, data from this study will not be presented in public before the main results are published without the prior consent of the TSC. The success of the trial depends on a large number of neonatal nurses, neonatologists and parents. For this reason, chief credit for the results will not be given to the committees or central organisers, but to all who have collaborated and participated in the study. Acknowledgement will include all local co-ordinators and collaborators, members of the trial committees, the Trial Co-ordinating Centre and trial staff. Authorship at the head of the primary results paper will take the form "The BOOST-II UK Collaborative Group". This avoids giving undue prominence to any individual. All contributors to the study will be listed at the end of the report, with their contribution to the study identified.
Those responsible for other publications reporting specific aspects of the study, such as detailed ophthalmic outcomes, may wish to utilise a different authorship model, such as "[name], [name] and [name] on behalf of the BOOST-II UK Collaborative Group". Decisions about authorship of additional papers will be discussed and agreed by the trial investigators and the TSC.
Parents will be sent a summary of the final results of the study, which will contain a reference to the full paper. A copy of the journal article will be available on request from the NPEU.
Investigator Agreement
"I have read this protocol and agree to abide by all provisions set forth therein. 
